Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Immunovaccine reports Phase Ib data of DPX-Survivac plus epacadostat for ovarian cancer

In December, Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF) reported top-line data from 10 evaluable patients with platinum-sensitive or -resistant ovarian cancer in the first dose cohort of a Phase

Read the full 275 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE